The North America Veterinary Dermatology Drugs Market would witness market growth of 7.4% CAGR during the forecast period (2021-2027).
Currently, over one-fifth of all animal veterinary meetings are related to dermatological issues. Conditions such as allergies, seborrhoeic dermatitis, otitis externa, and surface pyoderma are some of the commonly diagnosed dermatological conditions. The veterinary dermatology market is still demanding massive improvements in the animal dermatology industry and thus, there is a development in innovating new drugs for the veterinary service.
With the development in the safety and efficacy studies, there have been significant developments made for equine lameness and the makers are willing to boost production capabilities and distribution of the drugs, thereby assisting horses around the world. In the last few years, constant developments in equine dermatological drugs are assisting in treating common diseases like fungal infection, skin inflammation, or an infectious bacterium in horses. The demand for veterinary dermatology drugs would be driven by the fact that the prevalence of diseases in horses is very high around the globe.
North America emerged as the dominant region in the overall veterinary dermatology drugs market and is expected to showcase a similar kind of trend during the forecasting period. The growth of the regional market includes the higher adoption rate of companion animals in well-established nations like Canada, US, and higher expenditure on pet care in this region. According to the American Pet Products Association (APPA) data reveals that 68% of US households, or around 86.4 million homes, have a minimum of one pet.
Conversely, the growth of the regional market would further be driven by the massive prevalence of pruritus, alopecia, sores, masses, pustules, scales, eruptions, seborrhea, and draining tracts in companion animals. Moreover, a key driver for the regional market is the surge in technology in veterinary medicine that has expanded the lifespan of veterinary animals.
The US market dominated the North America Oral Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $1,354.1 million by 2027. The Canada market is experiencing a CAGR of 9.1% during (2021 - 2027). Additionally, The Mexico market would witness a CAGR of 8.1% during (2021 - 2027).
Based on Route of Administration, the market is segmented into Topical, Injectable and Oral. Based on Distribution Channel, the market is segmented into Retail, Hospital Pharmacies and Online. Based on Drug Indication, the market is segmented into Parasitic Infections, Allergic Infections and Other Indications. Based on Animal Type, the market is segmented into Companion Animal and Livestock Animal. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Veterinary Dermatology Drugs Market is Estimated to reach $13.6 Billion by 2027, at a CAGR of 8.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck Group, Elanco Animal Health, Inc., Zoetis, Inc., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Vetoquinol SA (Soparfin SCA), Virbac, Bioibérica, S.A.U., Bimeda, Inc., and Ceva Santé Animale.
By Route of Administration
By Distribution Channel
By Drug Indication
By Animal Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
